L-Glutamine Oral Therapy Reduces Sickle Cell-Related Pain Better Than Placebo
L-Glutamine oral treatment with or without hydroxyurea reduces pain crises better than placebo in individuals with sickle cell disease.
Sickle Cell Disease
Chronic Pain Leads to Higher Opioid Doses and Lower QoL in Sickle Cell Patients
In adults with sickle cell disease, higher daily opioid use may be associated with poorer health-related quality of life.
Olinciguat Granted Orphan Drug Status for Sickle Cell Disease
Olinciguat is a soluble guanylate cyclase stimulator currently in Phase 2 development.
Predictive Ability of Intermittent Pain Diaries in Sickle Cell Disease
In patients with sickle cell disease, review of intermittent pain diaries using a single random day per week or a single week per month was shown to be comparable to review of 5 months’ worth of pain diaries.
New Sickle Cell Disease Treatment Gets FDA Approval
The FDA has approved Endari to reduce acute complications of sickle cell disease in patients aged ≥5 years.
Diagnostic Criteria for Chronic Sickle Cell Disease-Related Pain
A new evidence-based classification system for chronic sickle cell disease pain was recently published.
Treatment May Alleviate Sickle Cell-Related Pain
Crizanlizumab therapy resulted in a significantly lower rate of sickle cell-related pain crises.
Next post in Treatments
